Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 8/20 | 0.44 |
| ▸ | RAB9A | P51151 | 8/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.43 |
| ▸ | RELA | Q04206 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7683643 | 0.83 | L3MBTL1 (0.40) | L3MBTL1NUDT1NPC1RAB9AALDH1A1 | |
| SCHEMBL2289473 | 0.79 | SRC (0.50) | L3MBTL1NUDT1SMN1; SMN2NPSR1GAA | |
| SCHEMBL418310 | 0.76 | NUDT1 (0.46) | L3MBTL1NUDT1 | |
| SCHEMBL335977 | 0.76 | NUDT1 (0.58) | L3MBTL1NUDT1NPC1RAB9AALDH1A1 | |
| SCHEMBL325223 | 0.75 | NUDT1 (0.42) | L3MBTL1NUDT1ALDH1A1KDM4ENPSR1 | |
| SCHEMBL6370683 | 0.75 | NUDT1 (0.42) | L3MBTL1NUDT1ALDH1A1KDM4ENPSR1 | |
| SCHEMBL13574520 | 0.75 | CYP2A6 (0.41) | L3MBTL1NUDT1FLT1CDK8CDK9 | |
| SCHEMBL1507164 | 0.74 | NUDT1 (0.45) | L3MBTL1NUDT1NPC1RAB9AALDH1A1 | |
| SCHEMBL1041231 | 0.74 | NUDT1 (0.45) | L3MBTL1NUDT1ALDH1A1KDM4ETP53 | |
| SCHEMBL2652721 | 0.74 | NUDT1 (0.45) | L3MBTL1NUDT1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116096717-A | Imidazo [1,2-a ] pyridine and [1,2,4] triazolo [1,5-a ] pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis | 百时美施贵宝公司 | 2023-05-09 | — | — | CN | claimed |
| US-9018217-B2 | Phenylimidazole derivatives as PDE10A enzyme inhibitors | H. LUNDBECK A/S (DK) | 2015-04-28 | — | — | US | claimed |
| US-20150025081-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2015-01-22 | — | — | US | claimed |
| EP-2318394-B1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | LUNDBECK & CO AS H (DK) | 2014-01-22 | — | — | EP | claimed |
| US-20120135987-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2012-05-31 | — | — | US | claimed |
| JP-2011524381-A | — | — | 2011-09-01 | — | — | JP | claimed |
| WO-2011072695-A1 | PHENYLIMIDAZOLE DERIVATIVES COMPRISING AN ETHYNYLENE LINKER AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2011-06-23 | — | — | WO | claimed |
| EP-2318394-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. Lundbeck A/S (DK) | 2011-05-11 | — | — | EP | claimed |
| US-20100016303-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2010-01-21 | — | — | US | claimed |
| WO-2009152825-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2009-12-23 | — | — | WO | claimed |
| EP-0204285-A1 | Imidazoheterocyclic compounds processes for preparation thereof and pharmaceutical compositions comprising them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-12-10 | — | — | EP | claimed |
| WO-2024231852-A1 | SUBSTITUTED BIPHENYL COMPOUNDS AS CBL-B INHIBITORS | GLENMARK PHARMACEUTICALS LTD (IN) | 2024-11-14 | — | — | WO | disclosed |
| EP-4447954-A1 | HETEROCYCLIC COMPOUNDS AS 5HT2A BIASED AGONISTS | Icahn School of Medicine at Mount Sinai (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-4141898-A | Imidazo pyridinium quaternary salts as hypoglycemic agents | PFIZER INC. (US) | 1979-02-27 | — | — | US | disclosed |
| US-4129567-A | IMIDAZOPYRIDINES AND ISOB IDINE | PFIZER INC. (US) | 1978-12-12 | — | — | US | disclosed |
| US-4097598-A | Quaternary salts as hypoglycemic agents | PFIZER INC. (US) | 1978-06-27 | — | — | US | disclosed |
| US-4093616-A | PYRROLO(1,2-A)PYRAZINIUM, PYRAZOLO(1,5-A)PYRIDINIUM, 1H-IMIDAZO(2,1-A)ISOQUINOLINIUM, OR IMIDAZO(5,1-A)ISOQUINOLINIUM SALTS | PFIZER INC. (US) | 1978-06-06 | — | — | US | disclosed |
| US-4044015-A | Imidazopyridinium compounds as hypoglycemic agents | PFIZER INC. (US) | 1977-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016303-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | PDE10A, PDE5A, PDE3B | L3MBTL1 4579/4885NUDT1 336/4885NPC1 1261/4885 |
| US-20120135987-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | PDE10A, PDE5A, PDE3B | L3MBTL1 4579/4885NUDT1 336/4885NPC1 1261/4885 |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | KEAP1, NQO1, NFE2L2 | L3MBTL1 203/4885NUDT1 1629/4885NPC1 350/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | L3MBTL1 3066/4885NUDT1 407/4885NPC1 39/4885 |
| US-20150025081-A1 | NOVEL PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | PDE10A, PDE5A, PDE3B | L3MBTL1 4579/4885NUDT1 336/4885NPC1 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.